Repeat & Correct: Yangzijiang Shipbuilding's Orders Signal Strong Revenue Stream — Market Talk
("Yangzijiang Shipbuilding's Orders Signal Strong Revenue Stream -- Market Talk" at 0739 GMT on May 28 misstated the currency and the year-to-date order-win figure. The correct version follows: )
0739 GMT - Yangzijiang Shipbuilding's order momentum is likely to continue into FY 2028, suggesting solid revenue ahead, Citi Research analyst Luis Hilado says in a note. The Singapore-listed shipbuilder's 1Q update showed a robust order book, with year-to-date wins of US$3.32 billion against the company's 2024 target of US$4.5 billion, the analyst says. "The stock continues to offer healthy upside from current levels from riding the industry upcycle, in our view," he adds. Citi maintains a buy rating on the stock and raises its target price to S$2.45 from S$1.84. Shares are 3.6% higher at S$2.00. (amanda.lee@wsj.com)
(END) Dow Jones Newswires
July 18, 2024 03:47 ET (07:47 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks
United States